Respiratory syncytial virus (RSV) is a familiar seasonal illness, but the tools to prevent it are new. Canada has recently approved vaccines for older adults and pregnant people, along with a long-acting monoclonal antibody that can protect infants through their first RSV season.
These innovations offer new ways to reduce hospitalizations and severe illness. Yet whether Canadians can access them still depends largely on where they live.
Across the country, provincial RSV programs vary widely in eligibility, scope and public funding — see, for example, Ontario RSV program updates and Alberta immunization program information.
